Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | Single-cell technologies as powerful tools to understand AML heterogeneity

Peter van Galen • 21 Mar 2023
ISAL 2023
Acute Myeloid Leukemia Leukemia

Peter van Galen, PhD, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston, MA, explains how single-cell technologies allow studying heterogeneity in acute myeloid leukemia (AML) and can help us better understand how to target the disease. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Peter van Galen

2:00
Using single-cell approaches to study & prevent the progression of clonal hematopoeisis to leukemia
Peter van Galen • 21 Mar 2023
1:28
Evolution of clonal hematopoiesis to BPDCN
Peter van Galen • 21 Mar 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals